Sigilon Therapeutics, Inc.
Sigilon Therapeutics, Inc. (SGTX): 5 pipeline candidates · ~28 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
27.5 months
D/E 1.02 · 0% dilution
Lead: Phase 1/Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for Sigilon Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$20.9M
Quarterly Burn
$4.2M
Runway
27.5 mo
Revenue
$5.9M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| mps-1 program | Preclinical |
| sig-001 | Phase 1/Phase 2 |
| sig-002 | Preclinical |
| sig-005 | Phase 1 |
| sig-007 | Preclinical |
Frequently asked questions
How many drug candidates are in Sigilon Therapeutics, Inc.'s pipeline?
Sigilon Therapeutics, Inc. (SGTX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sigilon Therapeutics, Inc.'s lead drug candidate?
Sigilon Therapeutics, Inc.'s most advanced tracked candidate is mps-1 program (Preclinical) for mucopolysaccharidosis type 1.
What is Sigilon Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sigilon Therapeutics, Inc. has approximately 27.5 months of cash runway.
Who is the CEO of Sigilon Therapeutics, Inc.?
Rogerio Vivaldi Coelho, M.D. is the chief executive officer of Sigilon Therapeutics, Inc. (SGTX).
Get the full picture on Sigilon Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.